Article Document Academic Article Information Content Entity Continuant Continuant Journal Article Entity Entity Generically Dependent Continuant 2025-06-23T23:33:05 RDF description of Continuous intravenous anakinra infusion to calm the cytokine storm in macrophage activation syndrome - http://repository.healthpartners.com/individual/document-rn21110 28010 ACR open rheumatology Coronavirus Infections <p>OBJECTIVE: The objective of this study was to report the benefit of a therapeutic approach consisting of intravenous (IV) continuous anakinra (recombinant human interleukin-1 receptor antagonist) infusions in treating severely ill adult patients with secondary hemophagocytic lymphohistiocytosis or macrophage activation syndrome (MAS). METHODS: A retrospective chart review of five patients treated at Regions Hospital from 2016 to 2019 was conducted. Demographic, clinical, and laboratory characteristics and outcomes were recorded. RESULTS: Continuous IV anakinra infusions up to 2400 mg/d resulted in rapid serologic, then clinical response in 4 of 5 severely ill patients who were refractory to all other therapies, including subcutaneous anakinra. Subsequently, 3 of 5 patients have been maintained on anakinra or canakinumab, with no recurrence of MAS. CONCLUSION: Continuous infusion of IV anakinra may result in rapid serologic and subsequent clinical improvement in adult patients with MAS. This method for treating cytokine storm should be considered in the current COVID-19 pandemic in the subgroup of patients with severe disease who have a cytokine storm presentation.<p> 10.1002/acr2.11135 Continuous intravenous anakinra infusion to calm the cytokine storm in macrophage activation syndrome 5 COVID-19 public Arthritis 16745 2 Retrospective Studies document-rn21110 Drugs and Drug Therapy 2022-02-21T22:48:57.408-06:00